Seagen Stockholders Approve Acquisition by Pfizer
30 Maio 2023 - 4:22PM
Business Wire
Following a special meeting of its stockholders, Seagen Inc.
(Nasdaq: SGEN) today announced that its stockholders voted to
approve a proposal to adopt the previously announced merger
agreement under which Pfizer will acquire Seagen for $229 per share
in cash. More than 99% of the shares voted at the meeting,
representing approximately 88% of the shares of Seagen common stock
issued and outstanding as of the record date for the special
meeting, were voted in favor of the proposal to adopt the merger
agreement.
“We are pleased with the outcome of today’s special meeting vote
to approve Seagen’s acquisition by Pfizer and thank our
stockholders for their support for this compelling transaction,”
said David Epstein, Chief Executive Officer of Seagen. “The
affirmative vote brings us one step closer to joining with Pfizer
to accelerate our ability to deliver transformative cancer
medicines to more patients in need around the world.”
Seagen will file the final, certified voting results in a Form
8-K with the U.S. Securities and Exchange Commission.
Subject to the fulfillment of customary closing conditions,
including receipt of required regulatory approvals, the acquisition
is expected to close in late 2023 or early 2024.
About Seagen
Seagen is a global biotechnology company that discovers,
develops and commercializes transformative cancer medicines to make
a meaningful difference in people’s lives. Seagen is headquartered
in the Seattle, Washington area, and has locations in California,
Canada, Switzerland and the European Union. For more information on
the company’s marketed products and robust pipeline, visit
www.seagen.com and follow @SeagenGlobal on Twitter.
Cautionary Statement Regarding
Forward-Looking Statements
Information set forth in this press release, including
statements as to the expected timing, completion and effects of the
proposed transaction between Seagen and Pfizer, constitute
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Actual results or developments may differ materially from those
projected or implied in these estimates and statements. Such
estimates and statements include, but are not limited to,
statements about the benefits of the transaction, expected closing
of the transaction and other statements that are not historical
facts. Such statements are based upon the current beliefs and
expectations of the management of Seagen and are subject to
significant risks and uncertainties outside of our control. Among
the risks and uncertainties that could cause actual results to
differ from those described in the forward-looking statements are
the following: the occurrence of any event, change or other
circumstances that could give rise to the termination of the merger
agreement; the risk that the necessary regulatory approvals may not
be obtained or may be obtained subject to conditions that are not
anticipated; risks that any of the other closing conditions to the
proposed transaction may not be satisfied in a timely manner; risks
related to litigation brought in connection with the proposed
transaction; risks related to financial community and rating agency
perceptions of Seagen and its business, operations, financial
condition and the industry in which it operates; risks related to
disruption of management time from ongoing business operations due
to the proposed merger; effects of the announcement, pendency or
completion of the proposed merger on the ability of Seagen to
retain customers and retain and hire key personnel and maintain
relationships with suppliers and partners, and on Seagen’s
operating results and businesses generally; and risks related to
the potential impact of general economic, political and market
factors on the parties to the proposed merger or the proposed
merger.
Discussions of additional risks and uncertainties are contained
in Seagen’s filings with the SEC. Seagen is under no obligation,
and expressly disclaims any obligation, to update, alter, or
otherwise revise any forward-looking statements, whether written or
oral, that may be made from time to time, whether as a result of
new information, future events, or otherwise. Persons reading this
press release are cautioned not to place undue reliance on these
forward-looking statements which speak only as of the date
hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230530005610/en/
For Investors Douglas Maffei, Ph.D. Vice President, Investor
Relations (425) 527-4881 dmaffei@seagen.com
For Media David Caouette Vice President, Corporate
Communications (310) 430-3476 dcaouette@seagen.com
Seagen (NASDAQ:SGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Seagen (NASDAQ:SGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024